Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin Oct 26 | 2018Biocon CY Q3 '18 (FY Q2 '19) Earnings UpdatePurchase Blast$599
Posted in: GLP-1RA, GLP-1RA + Basal Oct 26 | 2018Oral Semaglutide + Basal Insulin (PIONEER 8) Positive Topline ResultsPurchase Blast$599
Posted in: Basal Insulin, DPP-IVi, Dual/triple agonist, SGLT2i Oct 25 | 2018Merck Q3 ’18 Earnings Update; No BS-Glargine DiscussionPurchase Blast$599
Posted in: Basal Insulin, GLP-1RA Oct 23 | 2018New Sanofi Efpeglenatide + Glargine Study (AMPLITUDE-L)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Insulin Delivery Oct 23 | 2018Novo Partners with Flex for Connected Care Data ManagementPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin Oct 23 | 2018Novo to Launch Connected Pens and New Connected Care Partnerships with Dexcom, Roche, and GlookoPurchase Blast$599
Posted in: Glucagon Oct 23 | 2018Xeris Glucagon Filing Accepted by FDA; June 10, 2019 PDUFAPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Oct 18 | 2018Dexcom G6 Medicare Availability in Early 2019; New Data Partnership with ValidicPurchase Blast$599
Posted in: Glucose Monitoring Oct 18 | 2018Dexcom G6 Medicare Availability in Early 2019; New Data Partnership with ValidicPurchase Blast
$599
Posted in: GLP-1RA, Topics Oct 17 | 2018New Ozempic “Real-World Pragmatic Study” with AnthemPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Oct 17 | 2018Abbott and Roche Q3 '18 Earnings UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Topics Oct 16 | 2018MannKind Receives Warning for Afrezza Facebook PromoPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Oct 16 | 2018J&J Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i, Topics Oct 15 | 2018AZ’s Head of CVRM Joins NovoPurchase Blast
$599
Posted in: Bolus Insulin, Topics Oct 12 | 2018Novo’s Onset 7 Fulfills Pediatric Post-Marketing CommitmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Topics Oct 11 | 2018Tidepool to Support Loop; New Study on Insulin Variability in US PharmaciesPurchase Blast
$599
Posted in: Basal Insulin, Topics Oct 11 | 2018Merck Cancels Bs-glargine Agreement with SamsungPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, SGLT2i, Topics Oct 05 | 2018New ADA/EASD Guidelines Recommend GLP-1RA Over Insulin and Make Other New H2H Drug RecommendationsPurchase Blast
$599
Posted in: Dual/triple agonist, Topics Oct 04 | 2018Lilly Dual Agonist Ph3 Analysis; EASD Investor PresentationPurchase Blast
$599
Posted in: DPP-IVi, Topics Oct 04 | 2018CARMELINA Neutral on CV and Renal Outcomes; No Increased hHF RiskPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
